MTVA
MetaVia Inc. Common StockMTVA
MTVA
About: MetaVia Inc is a clinical-stage biotechnology company focused on developing novel pharmaceuticals to treat cardiometabolic diseases. It has two programs focused on the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and obesity. DA-1241 is a novel G-Protein-Coupled Receptor 119 (GPR119) agonist with development optionality as a standalone and/or combination therapy for both MASH and Type 2 Diabetes Mellitus (T2DM). DA-1726 is a novel oxyntomodulin (OXM) analogue functioning as a GLP-1 receptor (GLP1R) and glucagon receptor (GCGR) dual agonist for the treatment of obesity that is designed to be administered once weekly subcutaneously.
Employees: 8
0
Funds holding %
of 7,425 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
100% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 2
15% more funds holding
Funds holding: 13 [Q3] → 15 (+2) [Q4]
0% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 2
2.39% less ownership
Funds ownership: 12.89% [Q3] → 10.51% (-2.39%) [Q4]
47% less capital invested
Capital invested by funds: $3.47M [Q3] → $1.84M (-$1.63M) [Q4]
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
Low target
$12
1,477%
upside
Avg. target
$12
1,477%
upside
High target
$12
1,477%
upside
1 analyst rating
1 positive
100%
0 neutral
0%
0 negative
0%
HC Wainwright & Co. Ed Arce 39% 1-year accuracy 59 / 151 met price target | 1,477%upside $12 | Buy Reiterated | 16 Apr 2025 |
Financial journalist opinion
Based on 3 articles about MTVA published over the past 30 days
Neutral
PRNewsWire
1 week ago
MetaVia Announces Late-Breaking Poster Presentation on DA-1241 at the EASL Congress 2025
CAMBRIDGE, Mass. , April 23, 2025 /PRNewswire/ -- MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that an abstract highlighting data from its Phase 2a clinical trial of DA-1241, a novel G-Protein-Coupled Receptor 119 (GPR119) agonist, in patients with presumed metabolic dysfunction-associated steatohepatitis (MASH), has been accepted as a late-breaking poster presentation at the European Association for the Study of the Liver (EASL) Congress 2025, taking place May 7-10, 2025 in Amsterdam, the Netherlands.
Neutral
PRNewsWire
1 week ago
MetaVia Reports Additional Positive Top-Line Results From the MAD Part 2 of Its Phase 1 Study of DA-1726, a Novel 3:1 Ratio GLP-1 and Glucagon Dual Receptor Agonist to Treat Obesity, Further Demonstrating Its Best-In-Class Potential
A Dose-Dependent Response in Body Weight Reduction Was Observed Between 8 mg and 32 mg Doses Change in BMI and Body Weight Adjusted for Height In the Treatment Groups, Showed a Significant Difference Compared to Placebo, Indicating Potentially Greater Efficacy with Increasing Dosage and Longer Duration of Use No Drug-Induced Cardiovascular Effects Were Observed In Heart Rate or QTcF Measurements of Subjects Receiving up to 32 mg of DA-1726 at 4-Weeks Additional Cohorts Being Added to Determine Maximum Tolerated Dose CAMBRIDGE, Mass. , April 22, 2025 /PRNewswire/ -- MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today reported additional top-line results from the multiple ascending dose (MAD) Part 2 of its Phase 1 clinical trial of DA-1726, a novel, dual oxyntomodulin (OXM) analog agonist that functions as a glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR), further demonstrating its potential as a best-in-class obesity drug.
Neutral
PRNewsWire
2 weeks ago
MetaVia Announces Positive Top-Line Data From the 4-Week Phase 1 MAD Trial of DA-1726, a Novel 3:1 Ratio GLP-1 Glucagon Dual Receptor Agonist to Treat Obesity, Showing Compelling Weight Loss and Safety Effects With Potential Best-In-Class Glucose Control (GLP-1R), Waist Reduction (GCGR), and Tolerability
With No Titration, Demonstrated Compelling Maximum Weight Loss of 6.3% and Mean Weight Loss of 4.3% at Day 26 at 32 mg Dose (p=0.0005) Demonstrated Strong Signal of GLP-1R Efficacy with Maximum Lowering of Fasted Glucose of -18 mg/dL and Mean Lowering of -5.3 mg/dL at Day 26 at 32 mg Dose Maximum Waist Circumference Reduction of 3.9 Inches and Mean Reduction of 1.6 Inches Demonstrates Strong Signal of Glucagon Efficacy at Day 33 at 32 mg Dose Additional Cohorts Being Added to Determine Maximum Tolerated Dose Planned Phase 1 Part 3 to Include Wegovy® Early Drop-Out Patients to Explore Potential Superiority of DA-1726 on Safety and Tolerability, Along With Weight Loss and Other Secondary Endpoints CAMBRIDGE, Mass. , April 15, 2025 /PRNewswire/ -- MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced positive results from the 4-week multiple ascending dose (MAD) Part 2 of its Phase 1 clinical trial of DA-1726, a novel, dual oxyntomodulin (OXM) analog agonist that functions as a glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR), for the treatment of obesity.
Neutral
PRNewsWire
1 month ago
MetaVia Reports Year End 2024 Financial Results and Provides Corporate Update
Top-Line Data From MAD Part 2 of the Phase 1 Trial of DA-1726 Expected in April of 2025 Announced Positive Top-Line 16-Week Results from the Phase 2a Trial of DA-1241 for the Treatment of MASH, in December, Demonstrating Direct Hepatic Action in Addition to Its Glucose Lowering Effect $16.0 Million in Cash at End of Fourth Quarter E xpected to Fund the Company Into the Third Quarter of 2025 CAMBRIDGE, Mass. , March 20, 2025 /PRNewswire/ -- MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced financial results for the year ended December 31, 2024 and provided a corporate strategic update.
Neutral
PRNewsWire
3 months ago
MetaVia to Hold Advisory Committee Meeting at the 9th Annual MASH-TAG 2025 Conference
CAMBRIDGE, Mass. , Jan. 10, 2025 /PRNewswire/ -- MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that it is holding an Advisory Committee meeting today, at the 9th Annual MASH-TAG 2025 Conference, to discuss the previously announced positive top-line 16-week results from the two-part Phase 2a clinical trial of DA-1241, a novel G-Protein-Coupled Receptor 119 (GPR119) agonist, in patients with presumed metabolic dysfunction-associated steatohepatitis (MASH).
Charts implemented using Lightweight Charts™